VeriMomVeriMom
HIGH RISK

Hamilelikte minoxidil succinoyl oligopeptide-143 kullanmaktan kaçınmalı mıyım? | VeriMom

Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.

What to use instead

Pregnancy-safe ingredients that serve a similar function:

FAQ

minoxidil succinoyl oligopeptide-143 hamilelikte güvenli mi?
Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.
minoxidil succinoyl oligopeptide-143 emzirirken güvenli mi?
Minoxidil is a pharmacologically active systemic agent with reports of infant effects after maternal topical use and some evidence of transmission/infant exposure; regulatory guidance warns about infant hypertrichosis following skin contact. Thus breastfeeding safety is a concern (h=2). Mechanistic concern is demonstrated systemic exposure; measured transfer into milk is not well-quantified in public cosmetic dossiers, so exposure is graded as low but measurable for breastfeeding (e=1).
minoxidil succinoyl oligopeptide-143 bebek cildi için güvenli mi?
For dermal contact with infants (0–3 yr) there are case reports of excessive hair growth in infants after parental topical minoxidil use/contact, and infants have higher dermal uptake (immature barrier and higher surface-area-to-weight). Therefore hazard and mechanism scores follow minoxidil (h=2, m=2) and exposure is increased (adult e=2 → infant e=3 per your rules). No infant-specific toxicology studies for the peptide were found; the concern is driven by the minoxidil parent compound and case reports.
VeriMom minoxidil succinoyl oligopeptide-143 nasıl puanlıyor?
VeriMom minoxidil succinoyl oligopeptide-143'yi EU CosIng, ECHA sınıflandırmaları ve PubMed çalışmalarına göre 33/100 (yüksek risk) olarak puanlar.
Hamilelikte minoxidil succinoyl oligopeptide-143 yerine neler kullanılabilir?
Benzer işlevli ve bilinen riski olmayan alternatifleri içeren listemize bakın.

Her etiketi 2 saniyede kontrol et

VeriMom'u ücretsiz indirin — herhangi bir ürünü tarayın ve hamilelik güvenlik puanını anında görün.

Tıbbi Sorumluluk Reddi

Bu bilgiler yalnızca eğitim amaçlıdır ve tıbbi tavsiye niteliği taşımaz. Güvenlik puanları kamuya açık verilere dayanmaktadır ve tüm riskleri yansıtmayabilir. Hamilelik veya emzirme döneminde herhangi bir ürünü kullanmadan önce her zaman sağlık uzmanınıza danışın.

VeriMom uygulamasında tüm özellikleri keşfedin